FDA Approves First Generic Asthma Inhaler

FDA OKs First Generic Version of Widely Used Asthma Inhaler

About 42 million Americans have the conditions for which it can be used

Getty Images The first generic version of the popular Advair asthma inhaler has been approved by U.S. regulators. The Food and Drug Administration on Wednesday approved Mylan's version in three strengths for ages 4 and up. The inhalers are used twice daily to keep airways open and prevent flare-ups of wheezing, shortness of breath and other symptoms of asthma or chronic obstructive pulmonary disease. About 42 million Americans have those conditions. The device contains two medicines, inhaled in a precise mixture. That complexity has stymied a couple of other companies developing generic versions of GlaxoSmithKline's Advair Diskus inhaler, which costs about $400 a month. Generics generally are cheaper. Mylan didn't immediately respond to queries about when its inhaler, called Wixela Inhub, will be available or what the price will be. Cancel You are leaving AARP.org and going to the website of our trusted provider. The provider’s terms, conditions and policies apply. Please return to AARP.org to learn more about other benefits. Your email address is now confirmed. You'll start receiving the latest news, benefits, events, and programs related to AARP's mission to empower people to choose how they live as they age. You can also by updating your account at anytime. You will be asked to register or log in. Cancel Offer Details Disclosures

Close In the next 24 hours, you will receive an email to confirm your subscription to receive emails related to AARP volunteering. Once you confirm that subscription, you will regularly receive communications related to AARP volunteering. In the meantime, please feel free to search for ways to make a difference in your community at Javascript must be enabled to use this site. Please enable Javascript in your browser and try again.